Research programme: DNA vaccines - Inovio

Drug Profile

Research programme: DNA vaccines - Inovio

Alternative Names: Chikungunya virus DNA vaccine - Inovio; CHIKV vaccine - Inovio; Cytomegalovirus DNA vaccine - Inovio; dMab HIV - Inovio; DNA vaccine against HIV clade C - Inovio; INO 4500; INO 5400; INO-5401; Malaria vaccine - Inovio; Smallpox vaccine - Inovio; SynCon WT1 cancer immunotherapy

Latest Information Update: 19 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Inovio Pharmaceuticals
  • Developer Drexel University College of Medicine; Inovio Pharmaceuticals
  • Class AIDS vaccines; Bacterial vaccines; Cancer vaccines; DNA vaccines; Hepatitis C vaccines; Parasitic vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Smallpox

Highest Development Phases

  • Preclinical Cancer; Chikungunya virus infections; Clostridium infections; Cytomegalovirus infections; Hepatitis C; Human papillomavirus infections; Malaria; Malignant melanoma; Tuberculosis
  • Research Smallpox

Most Recent Events

  • 01 Jun 2017 Inovio Pharmaceuticals and Genentech enter into a collaboration to evaluate combination therapy of T cell immunotherapy and PD-L1 checkpoint inhibitor in Cancer
  • 01 Jun 2017 Inovio plans a phase Ib/II trial for Urogenital cancer (Combination therapy, Second-line therapy or greater, Late-stage disease, Unresectable/Inoperable, Metastatic disease)
  • 08 May 2017 Inovio Pharmaceuticals and Regeneron Pharmaceuticals enter into clinical agreement for conducting a phase I/II study in Glioblastoma (Newly diagnosed, Combination therapy)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top